Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arrowhead Pharmaceuticals, Inc. (ARWR)
Price$86.34Cached quote
Net income
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M | $243.2M | $138.3M | $88.0M | $168.8M | $16.1M | $31.4M | $158,333 | $382,000 | $175,000 | $290,266 | $146,875 | $296,139 | — | — | — | — | — | — | — | — |
| Research & development | $607.2M | $505.9M | $353.2M | $297.3M | $206.3M | $128.9M | $81.0M | $53.0M | $50.9M | $62.1M | $47.3M | $23.1M | $8.7M | $5.4M | $3.3M | $529,601 | — | — | — | — | — | — | — |
| Operating expenses | $731.1M | $604.6M | $445.7M | $421.7M | $287.3M | $181.2M | $107.6M | $72.1M | $68.4M | $81.9M | $96.4M | $53.5M | $24.9M | $21.2M | $10.1M | $5.8M | — | — | — | — | — | — | — |
| Operating income | $98.3M | −$601.1M | −$205.0M | −$178.5M | −$149.0M | −$93.2M | $61.2M | −$55.9M | −$37.0M | −$81.7M | −$96.0M | −$53.3M | −$24.6M | −$21.1M | −$9.8M | −$5.8M | — | — | — | — | — | — | — |
| Operating margin | 11.86% | −16,927.06% | −85.16% | −73.39% | −107.77% | −105.87% | 36.25% | −346.52% | −117.79% | −51,627.09% | −25,124.08% | −30,443.59% | −8,471.29% | −14,358.61% | −3,319.48% | — | — | — | — | — | — | — | — |
| EBITDA | $120.5M | −$584.2M | −$194.3M | −$169.8M | −$142.4M | −$89.0M | $63.9M | −$52.9M | −$34.0M | −$78.5M | −$93.6M | −$51.9M | −$22.8M | −$19.3M | −$9.6M | −$5.6M | — | — | — | — | — | — | — |
| EBITDA margin | 14.53% | −16,451.14% | −80.71% | −69.81% | −103.00% | −101.10% | 37.85% | −327.94% | −108.27% | −49,568.11% | −24,512.50% | −29,674.65% | −7,867.91% | −13,167.82% | −3,228.99% | — | — | — | — | — | — | — | — |
| Net income | −$1.6M | −$599.5M | −$205.3M | −$176.1M | −$140.8M | −$84.6M | $68.0M | −$54.5M | −$34.4M | −$81.7M | −$91.9M | −$58.6M | −$31.1M | −$21.1M | −$3.1M | −$5.8M | −$19.3M | −$27.2M | −$30.7M | −$20.0M | −$6.7M | −$751,255 | −$95,238 |
| Net profit margin | −0.20% | −16,882.37% | −85.27% | −72.39% | −101.85% | −96.09% | 40.27% | −337.32% | −109.46% | −51,614.64% | −24,068.29% | −33,502.97% | −10,729.22% | −14,383.61% | −1,056.56% | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.01 | -$5.00 | -$1.92 | -$1.67 | -$1.36 | -$0.84 | $0.72 | -$0.65 | -$0.47 | -$1.34 | -$1.60 | -$1.25 | -$1.30 | -$19.00 | -$4.40 | -$9.00 | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.01 | -$5.00 | -$1.92 | -$1.67 | -$1.36 | -$0.84 | $0.69 | -$0.65 | -$0.47 | -$1.34 | -$1.60 | -$1.25 | -$1.30 | -$1.90 | -$4.00 | -$9.00 | — | — | — | — | — | — | — |
Owners
Reported shareholders
10.51%of listed shares
BlackRock, Inc.14.83M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.51%14.83M shares |
Avoro Capital Advisors LLC | 8.05%11.36M shares |
FMR LLC | 5.70%8.04M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.50%6.35M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.33%6.11M shares |
STATE STREET CORP | 4.03%5.69M shares |
NORGES BANK | 2.76%3.9M shares |
Invesco Ltd. | 2.75%3.88M shares |
Anzalone Christopher Richard | ≈2.69%3.79M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.50%3.53M shares |
FRED ALGER MANAGEMENT, LLC | 2.34%3.3M shares |
BAKER BROS. ADVISORS LP | 1.41%1.99M shares |
Siren, L.L.C. | 1.22%1.72M shares |
Vestal Point Capital, LP | 1.12%1.58M shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 0.98%1.39M shares |
FIRST TRUST ADVISORS LP | 0.96%1.35M shares |
Driehaus Capital Management LLC | 0.96%1.35M shares |
Jupiter Topco LLC | 0.87%1.22M shares |
NORTHERN TRUST CORP | 0.85%1.19M shares |
DIMENSIONAL FUND ADVISORS LP | 0.84%1.18M shares |
Percentages use 141.14M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 12, 2026Form 4 · 10b5-1 | Lu HongboDirector | SellCommon Stock | 3.0K | $76.88 | $228.3K | 52.0K |
| Apr 23, 2026Form 4 · 10b5-1 | Hamilton James CChief Medical Officer | SellCommon Stock | 10.0K | $75.00 | $750.0K | 227.0K |
| Apr 22, 2026Form 4 · 10b5-1 | Apel Daniel JosephChief Financial Officer | SellCommon Stock | 8.7K | $71.92 | $627.9K | 162.9K |
| Apr 22, 2026Form 4 · 10b5-1 | Apel Daniel JosephChief Financial Officer | SellCommon Stock | 1.2K | $70.45 | $81.5K | 171.6K |
| Apr 22, 2026Form 4 · 10b5-1 | Apel Daniel JosephChief Financial Officer | SellCommon Stock | 3.2K | $70.11 | $224.9K | 172.8K |